Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
AC

NASDAQ · ACRV

Acrivon Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$2.21

Up+$0.01 (+0.45%)

Updated Aug 22, 2026, 11:17 PM

SID Score

6.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
47.65M
P/E ratio
-0.71
Dividend yield
0.00%
52-week range
$1.27 – $2.39
Volume
361.33K
Avg. volume
1.62M

Price performance

ACRV price history

1M range · 21 trading sessions · Daily adjusted prices

ACRV closed at $2.21 after 21 trading sessions, up 38.12% for the selected period.

Last close
$2.21
Period change
+38.12%
Period low
$1.43
Period high
$2.39
Daily close
View OHLC price history
ACRV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 21, 2026$2.21$2.31$2.18$2.21361.33K
Aug 20, 2026$2.33$2.37$2.17$2.20499.43K
Aug 19, 2026$2.06$2.39$2.06$2.39731.49K
Aug 18, 2026$2.05$2.065$1.97$2.05336.37K
Aug 17, 2026$2.11$2.14$1.96$2.051.5M
Aug 14, 2026$1.90$1.99$1.85$1.95758.08K
Aug 13, 2026$1.73$1.90$1.7037$1.85422.31K
Aug 12, 2026$1.75$1.75$1.70$1.72152.06K
Aug 11, 2026$1.78$1.78$1.69$1.73164.45K
Aug 10, 2026$1.77$1.78$1.73$1.74228.9K
Aug 7, 2026$1.73$1.7599$1.71$1.73302.25K
Aug 6, 2026$1.62$1.69$1.6018$1.69316.17K
Aug 5, 2026$1.61$1.65$1.59$1.64318.81K
Aug 4, 2026$1.57$1.61$1.555$1.56184.3K
Aug 3, 2026$1.52$1.58$1.482$1.56242.03K
Jul 31, 2026$1.57$1.64$1.50$1.50506.28K
Jul 30, 2026$1.43$1.54$1.41$1.52388.44K
Jul 29, 2026$1.50$1.5692$1.41$1.43774.05K
Jul 28, 2026$1.55$1.61$1.51$1.54235.43K
Jul 27, 2026$1.62$1.62$1.5511$1.56150.11K
Jul 24, 2026$1.68$1.68$1.60$1.60257.8K

Latest ACRV news

The latest Smart Investors Daily articles mentioning ACRV.

Stock researchCompany · Overview

ACRV research

Overview

Company profile and research snapshot.

Company profile

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$21.83
Implied upside
—
Analysts
15
ACRV recent ratings
DateFirmRatingTarget
Jan 9, 2026Piper SandlerOverweight—
Nov 25, 2025HC Wainwright & Co.Buy—
Aug 14, 2025OppenheimerOutperform—
May 16, 2025Jones TradingHold—
May 15, 2025OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 12, 2026

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor types advancing in randomized dose expansion phase supported by a promising, favorable safety profile and durable single-agent clinical activity in several tumor types Cash, cash equivalents, and marketable securities of $90.0 million as of June 30, 2026 expected to fund operations into fourth quart

Benzinga · Aug 12, 2026

Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of $(0.55) per share

Yahoo · Aug 5, 2026

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimization across AP3-informed solid tumor populations Dose expansion to evaluate biomarker-selected small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), lung adenocarcinoma (adNSCLC)

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By